Kiran Kaur Khush, MD

Publications

• Pregnancy-related human leukocyte antigen sensitization leading to cardiac allograft vasculopathy and graft failure in a heart transplant recipient: a case report. Ginwalla M, Pando MJ, Khush KK. Transplant Proc. 2013; 45 (2): 800-2
• Beta-adrenergic receptor polymorphisms and cardiac graft function in potential organ donors. Khush KK, Pawlikowska L, Menza RL, Goldstein BA, Hayden V, Nguyen J, Kim H, Poon A, Sapru A, Matthay MA, Kwok PY, Young WL, Baxter-Lowe LA, Zaroff JG. Am J Transplant. 2012; 12 (12): 3377-86
• Electrocardiographic characteristics of potential organ donors and associations with cardiac allograft use. Khush KK, Menza R, Nguyen J, Goldstein BA, Zaroff JG, Drew BJ. Circ Heart Fail. 2012; 5 (4): 475-83
• Influence of donor and recipient sex mismatch on heart transplant outcomes: analysis of the International Society for Heart and Lung Transplantation Registry. Khush KK, Kubo JT, Desai M. J Heart Lung Transplant. 2012; 31 (5): 459-66
• The 4G/4G genotype of the PAI-1 (serpine-1) 4G/5G polymorphism is associated with decreased lung allograft utilization. Sapru A, Zaroff JG, Pawlikowska L, Liu KD, Khush KK, Baxter-Lowe LA, Hayden V, Menza RL, Convery M, Lo V, Poon A, Kim H, Young WL, Kukreja J, Matthay MA. Am J Transplant. 2012; 12 (7): 1848-54
• Universal noninvasive detection of solid organ transplant rejection. Snyder TM, Khush KK, Valantine HA, Quake SR. Proc Natl Acad Sci U S A. 2011; 108 (15): 6229-34
• Differentially expressed RNA from public microarray data identifies serum protein biomarkers for cross-organ transplant rejection and other conditions. Chen R, Sigdel TK, Li L, Kambham N, Dudley JT, Hsieh SC, Klassen RB, Chen A, Caohuu T, Morgan AA, Valantine HA, Khush KK, Sarwal MM, Butte AJ. PLoS Comput Biol. 2010; 6 (9)
• Effect of pulmonary hypertension on clinical outcomes in advanced heart failure: analysis of the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) database. Khush KK, Tasissa G, Butler J, McGlothlin D, De Marco T. Am Heart J. 2009; 157 (6): 1026-34
• New developments in immunosuppressive therapy for heart transplantation. Khush KK, Valantine HA. Expert Opin Emerg Drugs. 2009; 14 (1): 1-21
• Association of African American race with elevated pulmonary artery diastolic pressure: data from the Heart and Soul Study. Khush KK, Shah SJ, Ristow B, De Marco T, Whooley MA, Schiller NB. J Am Soc Echocardiogr. 2007; 20 (11): 1307-13
• Donor cardiac troponin I levels do not predict recipient survival after cardiac transplantation. Khush KK, Menza RL, Babcock WD, Zaroff JG. J Heart Lung Transplant. 2007; 26 (10): 1048-53
• Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Khush KK, Waters DD, Bittner V, Deedwania PC, Kastelein JJ, Lewis SJ, Wenger NK. Circulation. 2007; 115 (5): 576-83
• Obese patients have lower B-type and atrial natriuretic peptide levels compared with nonobese. Khush KK, Gerber IL, McKeown B, Marcus G, Vessey J, Foster E, Chatterjee K, Michaels AD. Congest Heart Fail. 2006 Mar-Apr; 12 (2): 85-90
• Effects of statin therapy on the development and progression of heart failure: mechanisms and clinical trials. Khush KK, Waters DD. J Card Fail. 2006; 12 (8): 664-74
• Nesiritide acutely increases pulmonary and systemic levels of nitric oxide in patients with pulmonary hypertension. Khush KK, De Marco T, Vakharia KT, Harmon C, Fineman JR, Chatterjee K, Michaels AD. J Card Fail. 2006; 12 (7): 507-13
• A full house: complications from an uncorrected patent ductus arteriosus. Khush KK, Randhawa R, Israel E. Curr Cardiol Rep. 2005; 7 (4): 310-3
• Age and aneurysm position predict patterns of left ventricular dysfunction after subarachnoid hemorrhage. Khush K, Kopelnik A, Tung P, Banki N, Dae M, Lawton M, Smith W, Drew B, Foster E, Zaroff J. J Am Soc Echocardiogr. 2005; 18 (2): 168-74
• The history of the coronary care unit. Khush KK, Rapaport E, Waters D. Can J Cardiol. 2005; 21 (12): 1041-5
• Lessons from the PROVE-IT trial. Higher dose of potent statin better for high-risk patients. Khush KK, Waters D. Cleve Clin J Med. 2004; 71 (8): 609-16